Drug Profile
Nacolomab tafenatox
Alternative Names: C242 Fab-SEA; LS 4565; PNU 214565; PNV 214565Latest Information Update: 06 Aug 2002
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Developer Nonindustrial source; Pharmacia Corporation
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Pancreatic cancer
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 23 Mar 2000 A phase I study in patients with colorectal and pancreatic cancers has been added to the therapeutic trials and adverse events sections
- 24 Sep 1998 A study has been added to the therapeutics trials and immunogenicity sections